Epinex Diagnostics, Inc.

Changing The Paradigm In Point-of-Care Rapid Diagnostics

Raising $5,000,000
(

You can request access to view the full terms of this fundraise.

Request Access

Epinex Diagnostics has developed innovative, convenient and cost-effective tests that address unmet medical needs in some of the major worldwide healthcare issues of our time:

 - The Diabetes Epidemic (over 500 Million affected)
 
- Chronic Kidney Disease (over 850 Million affected)
 
- Atrial Fibrillation (over 50 Million affected)

Our tests help in prevention, monitoring, and screening of these diseases, improving healthcare outcomes and patient quality of life while bringing healthcare costs down across the world. These measures could have a huge impact globally.

For healthcare providers and their patients with conditions like diabetes, chronic kidney disease, and blood coagulation issues, consistent monitoring is a fact of life. However, existing traditional tests fail to meet their medical needs.

Diagnostics currently in the point of care (POC) and over the counter (OTC) healthcare  market are often:

Inaccurate

Cumbersome

Inefficient

Expensive

Epinex specializes in the development of rapid tests that address these vital medical needs by targeting gaps in both point-of-care and over-the-counter diagnostic tests.

With our proprietary technology platform and commitment to innovation, Epinex is prepared to manufacture and deploy three patented products:

This paradigm shift in technology will change the current healthcare standard by not only monitoring for these conditions ahead of time, bringing potential overall healthcare costs down, but also giving doctors and caregivers the tools to prevent these diseases to begin with.

Epinex SimplySure PT-INR is the first and only quantitative, non-electronic, whole blood coagulation test, putting rapid INR testing at patients’ fingertips. No external reader or device is needed.

SimplySure is ideal for individuals at risk of blood pooling and clotting due to atrial fibrillation and those on blood thinners who must consistently monitor the medication’s effectiveness.

Epinex ACR Rapid Test is the first lateral-flow rapid test application for the albumin to creatinine ratio. It can reveal early signs of kidney damage in patients at risk of developing kidney failure due to chronic diseases like hypertension and diabetes.

Epinex ACR Test Features:

Simple, proven technology.

Higher sensitivity than existing tests.

Greater dynamic range than existing tests.

Combines advantages and affordability.


Diabetes is the most important issue in healthcare today worldwide. The human and financial burden is enormous.

Current methods to diagnose and control diabetes (blood glucose testing and A1c) are not working. Recent research worldwide points to monthly testing for glycated albumin as a more effective paradigm for the monitoring and control of diabetes.

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.


Request Access

N

No updates yet.




%

No backers yet.




Quick Signup TBD

You must have an account to do this!


the startups.com platform

Copyright © 2019 Startups.com. All rights reserved.

Fundable is a software as a service funding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.